Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REPRONEX vs A.P.L.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing c AMP and promoting follicular development and estrogen synthesis.
A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Induction of ovulation in oligo-ovulatory or anovulatory women with functional hypothalamic-pituitary dysfunction (WHO Group II),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Induction of ovulation in anovulatory infertile women,Treatment of hypogonadism and cryptorchidism in males,Off-label: Assisted reproductive technology (ART) protocols
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
REPRONEX is a glycoprotein hormone that is cleared primarily by the liver and kidneys. The metabolic pathways involve proteolytic degradation. The terminal half-life is approximately 4-12 hours after subcutaneous administration.
Primarily via glucuronidation (60%) and sulfation (35%) in the liver, with a minor portion (5%) via CYP2E1 oxidation to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Approximately 10%; mainly albumin
80–90% bound to sex hormone-binding globulin (SHBG) and albumin.
0.2-0.5 L/kg; reflects distribution primarily in extracellular fluid
0.5–0.9 L/kg, indicating moderate tissue distribution (primarily gonads and liver).
SC/IM: nearly 100%
IM: 100%; Subcutaneous: ~80% (relative to IM); Oral: <5% (not clinically used).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²).
No specific adjustment required for mild to moderate renal impairment. In severe renal impairment (Cr Cl < 10 m L/min), extend dosing interval to every 8 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Caution in severe hepatic impairment; consider dose reduction or extended interval. Avoid use in active liver disease.
Not recommended for use in pediatric patients (safety and efficacy not established).
Weight-based: 10-15 mg/kg every 4-6 hours, not to exceed 5 doses per day or 75 mg/kg/day.
No specific dose adjustment; use with caution due to potential for decreased renal function and increased risk of thromboembolic events.
No specific dose adjustment, but consider renal and hepatic function and avoid exceeding 3000 mg/day.
REPRONEX should only be used by physicians who are experienced in infertility treatment and capable of monitoring ovarian response. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and potentially fatal. Multiple births have been reported.
No black box warning.
Risk of ovarian hyperstimulation syndrome (OHSS), which can be severe,Risk of multiple gestation,Thromboembolic events,Ovarian torsion,Pulmonary complications (e.g., atelectasis, adult respiratory distress syndrome)
May cause fluid retention, ovarian hyperstimulation syndrome (OHSS) in females,Increased risk of thromboembolic events,Precocious puberty in males,Not for use in prepubertal children unless for cryptorchidism
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,An organic intracranial lesion (e.g., pituitary tumor),Abnormal uterine bleeding of undetermined origin,Ovarian cyst or enlargement of unknown etiology,Pregnancy,Hypersensitivity to urofollitropin or any component
Hypersensitivity to chorionic gonadotropin or any component,Precocious puberty (in males),Prostatic carcinoma or other androgen-dependent neoplasms,Ovarian cyst or enlargement not due to polycystic ovary syndrome
No specific food interactions documented. Maintain adequate hydration to reduce OHSS risk. Avoid excessive alcohol or caffeine as they may affect fertility.
No known food interactions. Avoid alcohol during treatment.
REPRONEX (menotropins) is classified as FDA Pregnancy Category X. Studies have shown that menotropins can cause fetal harm when administered to a pregnant woman. There is no indication for use during pregnancy, as it is used for ovulation induction in infertility. If used inadvertently, there is a risk of multiple gestations and potential for congenital anomalies, but no specific teratogenic pattern has been established. Use is contraindicated in pregnant women.
A. P. L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided unless indicated for specific conditions. Data are limited; no increased fetal risk reported in inadvertent exposures. Second and third trimester use is not associated with teratogenicity but may increase risk of multiple gestation (if used for ovulation induction).
It is unknown whether menotropins are excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio is available.
Chorionic gonadotropin is not detected in breast milk following maternal administration. M/P ratio not established. Considered compatible with breastfeeding; no adverse effects on infant reported. Use with caution if high doses are administered.
REPRONEX is contraindicated in pregnancy and should not be used. No dosing adjustments are applicable as it is not indicated for use during pregnancy. Pharmacokinetic changes in pregnancy do not apply because the drug is not administered during pregnancy.
No pharmacokinetic studies in pregnancy. Dose adjustments are not typically required during pregnancy for standard indications. For ovulation induction, dosing is based on follicular development. In first trimester for luteal support, standard doses are used. No evidence of altered clearance or need for dose changes due to pregnancy.
REPRONEX (menotropins) is a gonadotropin preparation containing FSH and LH activity. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing and minimize ovarian hyperstimulation syndrome (OHSS) risk. Avoid use in primary ovarian failure. Administer intramuscularly; rotate injection sites. Concomitant h CG is required for final follicular maturation and ovulation trigger.
A. P. L. (chorionic gonadotropin) is used to trigger ovulation in assisted reproductive technology. Administer when follicles are mature (≥18 mm). Risk of ovarian hyperstimulation syndrome (OHSS) increases with higher doses. Monitor for abdominal pain, distension, and weight gain. Use caution in patients with prior thromboembolism.
Store REPRONEX in the refrigerator and protect from light.,Administer exactly as prescribed; do not change dose or schedule.,You may experience bloating, pelvic discomfort, or mood swings; report severe abdominal pain, nausea, or rapid weight gain (signs of OHSS) immediately.,Multiple pregnancy is possible; discuss risks with your doctor.,Use barrier contraception until instructed to attempt conception.,Do not drive or operate machinery if dizziness or visual disturbances occur.
This medication is given as an injection exactly as prescribed to trigger ovulation.,A single dose is usually sufficient; follow your doctor's timing instructions closely.,Common side effects include headache, fatigue, and injection site reactions.,Seek immediate medical help if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Report symptoms of blood clots: leg pain, chest pain, or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REPRONEX vs A.P.L., answered by our medical review team.
REPRONEX is a Gonadotropin that works by REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing c AMP and promoting follicular development and estrogen synthesis.. A.P.L. is a Gonadotropin that works by A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REPRONEX and A.P.L. depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REPRONEX is: Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.. The standard adult dose of A.P.L. is: 500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REPRONEX and A.P.L. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REPRONEX is classified as Category C. REPRONEX (menotropins) is classified as FDA Pregnancy Category X. Studies have shown that menotropins can cause fetal harm when administered to a pregnant woman. There is no indica. A.P.L. is classified as Category C. A.P.L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.